ClinicalTrials.gg
Active, not recruitingNCT06046950TETRAUpdated Sep 11, 2025

TrEatment Targets in Rheumatoid Arthritis: TETRA-study

An interventional study of Treatment target DAS28CRP-LDA and Treatment target SDAI-remission in Rheumatoid Arthritis, sponsored by Sint Maartenskliniek. Active, not recruiting at 1 site in Netherlands. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by Sint Maartenskliniek · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
340
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 154 studies in Arthritis, Rheumatoid with a site in Netherlands — 17 open to participants now, 26 under way, 1 of them phase 3. Arthritis, Rheumatoid · Netherlands.

Planned enrollment
43rd of 130
340 · median 150
Started
2023
with 2 others
No phase
11 of 154
4 open now
Primary completion
2027-02
later than 15 of 25 live
Registered
145th of 154
by date
Lead sponsor
4 of 154
Sint Maartenskliniek

Among the 154 studies in Arthritis, Rheumatoid with a site in Netherlands, this one is the 43rd largest by planned enrollment of the 130 interventional ones that give a count, is one of 3 that started in 2023, is one of 11 with no phase, reaches primary completion later than 15 of the 25 other live ones, and was the 145th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

17 of the 154 studies in Arthritis, Rheumatoid with a site in Netherlands are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Arthritis, Rheumatoid with a site in Netherlands, or all of them as a file.
02

Study summary

There is currently no cure for rheumatoid arthritis (RA), but many treatment options are available. The central aim of RA treatment is lowering disease activity. The proactive treatment strategy called treat to target (T2T) includes measuring disease activity, setting a target and adjusting treatment accordingly until the goal is reached. T2T has proven to be superior to usual care, but there is much debate regarding the most optimal treatment measure and target. The Disease Activity Score with 28-joint counts and c-reactive protein (DAS28CRP) low-disease activity (LDA) target and the more stringent Simplified Disease Activity Index (SDAI) remission target are the best validated targets. Especially the DAS28CRP is the most commonly used in research and practice, whereas the SDAI remission target is most recommended. The European Alliance of Associations for Rheumatology (EULAR) recommends to strive for remission, whereas the American College of Rheumatology (ACR) recommends to strive for LDA. In patients with new and established RA, the (cost)effectiveness of aiming for remission compared to LDA when starting and tapering antirheumatic drugs has not been directly compared. This study therefore aims to directly compare two T2T strategies, aiming at DAS28CRP-LDA and SDAI remission, in patients with established RA.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of RA (according to the 2010 or 1987 ACR/ EULAR classification criteria and/or clinical diagnosis)
  • (Starting) use of a DMARD
  • Aged 16 years or older
  • At most low disease activity, operationalised as DAS28-CRP \<3.5 (DAS28 CRP 2.9 cut off for low disease activity with measurement error 0.6) or SDAI \<19 (SDAI 11 cut off for low disease activity with measurement error of 8). A state of low disease activity is required at inclusion, as for RA patients in moderate or high disease activity there is no equipoise on the best course of action (treatment needs to be escalated).
  • Fluency of Dutch or English, both written and verbally; able to fill in questionnaires
  • Provided

Exclusion criteria

Exclusion Criteria:

  • Clinical deep remission, operationalised as SDAI \<3.3 or DAS28-CRP \<2.4, and an taper attempt in the past 2 years that was discontinued due to occurrence of flare.
  • Fewer than 3 DMARD treatment options left for this patient (severe difficult-to-treat or RA)
  • Current severe comorbidity or other serious life-shortening conditions hampering trial participation
  • Inability to comply with the study protocol or to provide with regard to intervention control and measuring outcomes
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
340 participants (estimated)

Study arms

  • Experimental
    DAS28CRP-LDA

    Arm that is allocated to strive for DAS28CRP low disease activity (LDA)

    Other: Treatment target DAS28CRP-LDA

  • Experimental
    SDAI-remission

    Arm that is allocated to strive for SDAI-remission

    Other: Treatment target SDAI-remission

Interventions

  • OtherTreatment target DAS28CRP-LDA

    Aiming for DAS28CRP-low disease activity

  • OtherTreatment target SDAI-remission

    Aiming for SDAI-remission

06

What researchers measure

Primary outcomes

  1. Achievement of the composite clinical/radiological remission outcome

    Achievement of the composite clinical/radiological remission outcome (radiographic progression ≤1 simple erosion narrowing score (SENS), AND, ≤1 swollen joint count, and being in PASS) at 18 months.

    Time frame: 18 months follow-up time point

Secondary outcomes

  1. The proportion of patients having radiographic progression (defined as > 1 simple erosion narrowing score (SENS) point) in both treatment arms

    Time frame: 18 months follow-up

  2. The number of swollen joints at 18 months follow-up

    Time frame: 18 months follow-up

  3. The proportion of patients achieving 'patient acceptable symptom state' (PASS)

    Time frame: 18 months follow-up

  4. The proportion of patients who reach the predefined target for each treatment arm (DAS28CRP-LDA or SDAI remission)

    Time frame: 18 months follow-up

  5. Percentage of patients that reach LDA or remission, using DAS28CRP- and SDAI-based definitions, in each treatment arm

    Time frame: 18 months follow-up

  6. Daily functioning, measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI)

    The Health Assessment Questionnaire-Disability Index (HAQ-DI) will be used to measure the impact of the rheumatoid arthritis on daily functioning. A minimum score of 0 and a maximum score of 60 can be scored. A higher score means a higher impact on daily functioning.

    Time frame: 18 months follow-up

  7. Quality of life (QoL) as defined by the 'EuroQol 5 Dimensions with 5 levels' (EQ5D-5L) questionnaire

    This questionnaire assesses five dimensions of health, including mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension can be answered on a 5-point scale, ranging from no problems to extreme problems/unable to. A higher score means a worse outcome.

    Time frame: 18 months follow-up

  8. Incidence density rates of safety ((serious) adverse events, according to CTCAE criteria version 5.0)

    Time frame: 18 months follow-up

  9. Drug use of the patients, consisting of the type and volume of antirheumatic drugs (glucocorticoids, DMARDS, NSAIDs) used over the 18 months period, and at 18 months visit

    Time frame: 18 months follow-up

  10. Costs associated with medical consumption as assessed with the 'Institute for Medical Technology Assessment Medical Consumption Questionnaire' (iMCQ)

    Time frame: 18 months follow-up

  11. Costs associated with loss of productivity as measured bij the 'Institute of Medical Technology Assessment Productivity Cost Questionnaire (iMTA PCQ)

    This is a short generic questionnaire that measures loss of productivity (e.g., both paid and unpaid work) due to illness or recovery.

    Time frame: 18 months follow-up

  12. Proportion of patients of whom the rheumatologist adhered to the local guidelines to treat the patients

    Clinicians are encouraged to adhere to protocol upfront, and adherence is actively monitored, but treatment decisions are ultimately made using shared decision making between patients and physicians. After study completion, adherence will be assessed through a comparison of the target measurements and any changes in treatment regime made by the rheumatologists.

    Time frame: 18 months follow-up

  13. The incidence density rate of flares

    Time frame: 18 months follow-up

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Feb 2027, 38 months after the start.

Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 38 months is above that.

Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2023
First posted
Sep 21, 2023
StartActual
Dec 20, 2023
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06046950
Lead sponsor
Sint Maartenskliniek
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Dec 20, 2023
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 11, 2025

Study contacts

Alfons Den Broeder, MD, PhD
principal investigator · Sint Maartenskliniek

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion